Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Research Strategy
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • Warm AIHA
      • COVID-19
      • IRAK1/4 Inhibitor
      • RIPK1 Inhibitor
    • Partnered Programs
      • Grifols
      • Kissei
      • Medison
      • BerGenBio
      • Aclaris Therapeutics
      • Daiichi-Sankyo
      • AstraZeneca
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Apr 16, 2007 7:30am EDT

Rigel to Present New Research Programs at AACR Meeting

Apr 11, 2007 7:30am EDT

Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma

Mar 14, 2007 7:30am EDT

Rigel Announces Presentation at the Lehman Brothers Global Healthcare Conference

Feb 13, 2007 7:30am EST

Rigel Announces Initiation of Phase 1 Study Evaluating R763 in Hematological Malignancies

Feb 07, 2007 7:30am EST

Rigel to Present at BIO CEO & Investor Conference 2007

Feb 06, 2007 7:30am EST

Rigel Announces Fourth Quarter and Year End 2006 Financial Results

Feb 01, 2007 7:30am EST

Rigel to Present at Upcoming Scientific Conferences

Jan 25, 2007 7:30am EST

Rigel Appoints Bradford S. Goodwin to Board of Directors

Jan 08, 2007 7:30am EST

Rigel Announces Initiation of Phase II Study Evaluating R788 in Immune Thrombocytopenic Purpura (ITP)

Jan 03, 2007 7:30am EST

Rigel to Present at Upcoming Keystone Symposium

  • Previous
  • 1…
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy

© 2021 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin